Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

About this trial

The purpose of this trial is to determine the safety and efficacy of the drug copanlisib and the optimum dose when used with trastuzumab emtansine (T-DM1). It will also establish how well copanlisib works in combination with trastuzumab emtansine (T-DM1) to treat anti HER2-therapy resistant breast cancer. The study will also be used to learn more about this new drug and this type of cancer.

Patient Profile

Advanced HER2-positive (HER2+) Breast Cancer

Where’s this trial being run?

Beaumont Hospital, Cork University Hospital, and St Vincents University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: Panthera
Number: 17-13
Full Title:

Phase Ib Clinical Trial of Copanlisib in Combination With Trastuzumab Emtansine (T-DM1) in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer (Panthera).

Principal Investigator: Prof Bryan Hennessy (Beaumont Hospital)
Type: In-House

Cancer Trials Ireland

Recruitment Started: Global: 2019
Ireland: 2019
Global Recruitment Target: 24
Ireland Recruitment Target: